These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies.
    Author: Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S.
    Journal: Eur J Immunol; 1993 Jul; 23(7):1671-7. PubMed ID: 7686858.
    Abstract:
    The mouse anti-idiotypic (anti-id) monoclonal antibody (mAb) MK2-23 bears the internal image of the determinant defined by the syngeneic immunizing anti-human high molecular weight melanoma-associated antigen (HMW-MAA) mAb 763.74, since it induces anti-HMW-MAA antibodies in syngeneic and xenogeneic hosts. To dissect the humoral immune response induced by mAb MK2-23 at the clonal level, 1351 hybridomas were generated from a BALB/c mouse immunized with mAb MK2-23. Serological and immunochemical assays showed that the anti-anti-idiotypic (anti-anti-id) mAb GH827, GH1002 and GH1081 react only with the immunizing anti-id mAb MK2-23 and that the anti-anti-id mAb GH149, GH368, GH464, GH518, GH586, GH704, GH786 and GH1151 react with both mAb MK2-23 and HMW-MAA. The eight HMW-MAA binding anti-anti-id mAb resembled mAb 763.74 in their reactivity patterns with a panel of cell lines, although the extent of reactivity was lower. Staining of surgically removed melanoma lesions detected subtle differences in the reactivity patterns of the eight HMW-MAA binding anti-anti-id mAb. This finding in conjunction with the differential ability of the eight anti-anti-id mAb to inhibit the binding of anti-HMW-MAA mAb 763.74 to melanoma cells and to mAb MK2-23 and with the different avidity of the binding to mAb MK2-23 suggest diversity in the fine specificity of the eight HMW-MAA binding anti-anti-id mAb. Like mAb 763.74, the eight HMW-MAA binding anti-anti-id mAb express the idiotopes recognized by the anti-id mAb MK2-23 and MK2-120. In contrast, the three anti-anti-id mAb GH827, GH1002 and GH1081, which do not bind HMW-MAA binding anti-anti-id mAb to the antibodies elicited by the membrane-bound HMW-MAA corroborates the validity of the use of anti-id mAb MK2-23 as an immunogen to implement active specific immunotherapy in patients with malignant melanoma.
    [Abstract] [Full Text] [Related] [New Search]